V-Bio Ventures is a venture capital firm that specializes in building and financing young, innovative life science companies. The firm focuses on early-stage investments in Europe and North America, aiming to transform scientific discoveries into solutions for unmet medical needs.

V-Bio Ventures is a venture capital fund that finds, builds and finances young, innovative companies in the life sciences arena. Our fund works closely with Belgium-based VIB, one of the world’s premier life science institutes. We invest throughout Europe in start-up and early-stage companies with high growth potential. We focus on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors.

Syndesi Therapeutics

V-Bio Ventures

Did you catch our latest newsletter? In these emails, we share exciting news from our portfolio companies and team, as well as articles with our thoughts on recent trends in innovation, investment, and life sciences!

We send out our newsletter three times per year, so make sure to sign up if you missed out and want to receive the next one!

https://lnkd.in/eQv_ZmP

#venturecapital #venturefunding #investmentnews #lifesciences #biotech #newsletter

V-Bio Ventures is very happy to announce the promotion of Charles Margarit, PhD from Analyst to Associate!

We’ve been witnessing a rush of fundraising for startups focusing on women’s health. From pre-clinical to clinical: more companies are entering the field and developing solutions for women’s unique needs. But is their focus broad and innovative enough? And are pharma companies paying attention?

Read our latest BioVox article by Aurelie Nowack about the gains and challenges to innovations in women's health: https://lnkd.in/emMgZhE2


#womenshealth #femtech


Congratulations are in order! We are happy to share that our portfolio company Orionis Biosciences has dosed their first patient in their phase 1 clinical trial of ORB-011, an attenuated, cis-targeted interferon immunotherapy based on the company’s A-Kine® platform. 
 
They have also announced a new appointment to its Board of Directors: Tony Fadell, co-inventor of the iPhone, founder of Nest, and Principal at Build Collective.
 
Read the press release here: https://lnkd.in/edvhkGyh

#oncology #immunotherapy #immunooncology #cytokines #venturecapital


Our portfolio company Muna Therapeutics is developing transformative therapies for neurodegenerative diseases. These drugs aim to preserve cognition and enhance the brain’s resilience in diseases like Alzheimer’s and Parkinson’s, providing much-needed hope for millions of patients and their loved ones. The multinational biotech – based in Denmark, Belgium, and the United States – was founded in 2020, rooted in the science of two world-class labs – Dr. Bart De Strooper of VIB and KU Leuven, and Dr. Simon Glerup of Aarhus University. 

Read this BioVox interview with Muna's CEO Rita Balice-Gordon to find out more about the company’s mission: https://lnkd.in/g2ru33Ds

#memoryloss #neurodegenerativediseases #alzheimers #parkinsons #multiplesclerosis #biotech #drugdiscovery

Pleased to announce that our portfolio company Agomab Therapeutics has raised $100 Million Series C! Agomab will be using the new capital to advance its fibrosis-focused pipeline, including its STENOVA Phase 2a clinical trial for lead candidate AGMB-129 in patients with Fibrostenosing Crohn’s Disease (FSCD).

Congratulations to Tim Knotnerus and his team on a great funding round. We look forward to supporting your continued clinical progress.

https://lnkd.in/eJ9eDzvr

#fibrosis #clinicaltrials #crohnsdisease #venturecapital 

VENTURES:V-BIO

V-Bio Ventures

Analysis Not Available